Skip to main content
    B

    Biofrontera Inc (BFRI)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.59
    +0.02 (+4.09%)

    Market Cap: $10.40M

    Last updated: Nov 17, 2026 at 4:35 PM ET

    Biofrontera Inc (BFRI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Biofrontera (BFRI) has a market cap of $10.40M and an enterprise value of $11.93M. Its share count is up 41.79% from a year earlier. Revenue grew 29.85% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 14.72% above the market cap, as debt exceeds cash.

    Market Cap$10.40M
    Enterprise Value$11.93M
    Latest price (Nov 17, 2026)$0.59

    Key Dates

    The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 16, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 18.24% in the quarter ended Sep 30, 2026 and grew 62.68% a year over 2 years.

    Shares Outstanding15.28M
    Shares Change (YoY)+41.79%
    Shares Change (QoQ)+18.24%
    Share Count Growth (2Y CAGR)+62.68%

    Valuation Ratios

    The price to sales ratio is 0.2x. Its year-end P/S ranged from 0.1x to 0.1x from 2023 to 2025.

    P/S Ratio0.2x
    Forward P/S0.2x

    Price Statistics

    The stock is down 27.44% over 52 weeks and trades 39.80% below its 50-day average.

    Beta (1Y)1.96
    52-Week Change-27.44%
    1-Month Change-26.36%
    3-Month Change-58.22%
    6-Month Change-26.39%
    5-Year Change-99.01%
    Total Return (1Y)-27.44%
    Total Return (3Y CAGR)-45.27%
    Total Return (5Y CAGR)-58.96%
    Max Drawdown (1Y)-64.60%
    Max Drawdown (3Y)-85.40%
    Sharpe Ratio (1Y)-0.37
    Correlation with SPY (1Y)0.31
    50-Day Average$0.98
    200-Day Average$1.03
    52-Week Range$0.56 to $1.66
    RSI (14 Days)29.9
    Average Volume (20 Days)201.08K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.78x current liabilities.

    Current Ratio0.78x
    Quick Ratio0.66x

    Returns and Efficiency

    Return on invested capital is -124.63% over the last 12 months.

    Return on Assets (ROA)-28.60%
    Return on Invested Capital (ROIC)-124.63%
    Return on Capital Employed (ROCE)-77.69%
    ROA (5Y Average)-52.29%
    Asset Turnover2.62x
    Inventory Turnover6.97x
    Receivables Turnover9.34x
    Cash Conversion Cycle-350 days

    Scores

    BFRI has an Altman Z-Score of -7.65, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-7.65
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $48.26M over the last 12 months.

    Revenue$48.26M
    Revenue Growth (YoY)+29.85%
    Gross Profit$38.40M
    Operating Income-$6.79M
    Pretax Income-$6.11M
    Net Income-$6.14M
    EBITDA-$4.95M
    EBIT-$5.62M
    Reported EPS (TTM)-$0.38

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$3.22M
    Total Debt$4.75M
    Net Debt$1.53M
    Net Debt Per Share$0.10
    Working Capital-$3.13M
    Shareholder Equity-$243.00K
    Tangible Book Value-$2.77M
    Total Assets$21.47M
    Total Liabilities$21.71M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$5.54M
    FCF Per Share-$0.37
    Depreciation and Amortization$662.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -14.06%, against a 5-year average of -61.85%.

    Gross Margin79.58%
    Operating Margin-14.06%
    Pretax Margin-12.67%
    Net Margin-12.72%
    EBITDA Margin-10.27%
    EBIT Margin-11.64%
    Gross Margin (5Y Average)74.53%
    Operating Margin (5Y Average)-61.85%
    Net Margin (5Y Average)-58.13%

    Growth

    Revenue grew 13.30% a year over 3 years.

    Revenue Growth (3Y CAGR)+13.30%
    Revenue Growth (5Y CAGR)+17.21%
    Book Value Per Share Growth (2Y CAGR)-36.61%
    Tangible Book Per Share Growth (2Y CAGR)-18.46%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-20 reverse split on Jul 5, 2023.

    Last Split DateJul 5, 2023
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 4 similar companies, BFRI has the 4th highest P/S.

    P/S Ratio0.2x vs 1.1x median
    ROIC-124.63% vs -18.14% median
    Revenue Growth (Trailing 4 Quarters, YoY)+29.85% vs +10.01% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 13.23% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+13.23%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BFRI

    What is BFRI's market cap?

    Biofrontera has a market cap of $10.40M. Its enterprise value, which adds debt and subtracts cash, is $11.93M.

    How many shares of BFRI are outstanding?

    Biofrontera has 15.28M shares outstanding. The count is up 41.79% from a year earlier.

    Does BFRI pay a dividend?

    No. Biofrontera does not pay a dividend.

    How much debt does BFRI have?

    Biofrontera has $4.75M of total debt and $3.22M of cash and equivalents, a net debt position of $1.53M.